Xenitra’s New Growth Engines Deliver Positive Gross Profit

Positive gross profit arrives before positive operating cash flow

Xenitra Limited (ASX:XEN) has crossed an important accounting threshold in its pivot away from its old structure: group gross profit reached A$310,005 in the September quarter, compared with a A$42,931 loss in the same period last year. The improvement came even as sales revenue fell 5.5% to A$6.133 million, making margin quality more important than headline turnover in this update.

The cash picture is less settled. The Appendix 4C records statutory net operating cash outflow of A$790,000, while management separately reported a A$700,687 outflow on its cash-plus-stablecoin measure. Xenitra finished the quarter with A$3.446 million in bank cash and A$372,001 of stablecoins, although the latter is separately classified and is not presented as statutory cash or a cash equivalent.

Pharmaceutical platform generates its first full-quarter revenue

The pharmaceuticals division supplied A$863,922 of September-quarter revenue and A$54,913 of gross profit, a 6.4% margin. That is an early result from the Hong Kong Fukang platform, which provides wholesaling capability, licences, logistics, warehousing and digital shopfronts. Xenitra said the margin reflects the initial trading mix and expects the product and channel mix to develop as the operation expands, but the filing does not quantify a timetable or target for that improvement.

Two procurement relationships give the division commercial routes to pursue. The Kangsheng agreement provides for at least A$12 million of pharmaceutical and health product purchases over three years, while the Joy Charm framework targets A$5 million of Food for Special Medical Purposes procurement over the same broad period. The agreements are fulfilled through individual purchase orders, so their headline values are procurement targets rather than guaranteed revenue. The division’s launch was previously supported by a A$12 million Kangsheng agreement, which marked the move from platform setup towards commercial execution.

Web3 margins are high, but sales remain small

Xenitra’s Web3 Commerce operation produced A$148,531 of sales revenue before A$40,998 in distributor rebates. Net sales of A$107,533 generated A$85,267 of gross profit, equivalent to a 79.3% gross margin. That is the most striking segment metric in the quarter, though it comes from pilot products at an early stage and still needs considerably more volume to absorb operating costs.

The XENShop platform is live, OPAL tokens have been minted and more than 500 distribution partners have been onboarded. Pilot partnerships with EZZ Life Sciences and Biomiq supported more than A$2 million of sales since April, according to the company, while September-quarter revenue reported for the Web3 division was limited to the pilot products. This distinction matters: historical launch sales and current-quarter revenue are not interchangeable measures. Xenitra also paid approximately A$338,000 in stablecoins towards Web3 ecommerce platform and artificial intelligence capabilities during the quarter, following the earlier OPAL tokenised sales launch that reported more than 400 distribution partners.

Equity funding supports a still cash-consuming transition

Financing supplied A$1.246 million during the quarter, partly offset by A$82,000 of transaction costs, while operating and investing activities consumed cash. Receipts from customers reached A$5.490 million in the statutory cash-flow report, against A$5.375 million of product manufacturing and operating payments, A$389,000 of staff costs and A$383,000 of administration and corporate costs.

Other operating expenses fell 35.6% year on year to A$336,934, but people costs rose to A$635,180 as Xenitra built a 52-person team across the two divisions. Management reports 4.84 quarters of available funding using bank cash plus the reported stablecoin balance and unused funding. However, the filing describes the A$372,000 amount as a USDT stablecoin wallet used for customer receipts and day-to-day Web3 expenses, rather than a conventional undrawn debt facility. That makes the quality and liquidity of the stated funding runway a point requiring close attention.

Repeat orders and cash conversion become the next test

Xenitra’s stated priority is to direct capital towards products and channels with stronger margins and more efficient cash conversion. Receivables increased by A$325,221 and inventory by A$293,976 during the quarter, predominantly in Web3, while higher payables provided a partial offset. The next phase therefore depends less on establishing infrastructure and more on converting that infrastructure into repeat pharmaceutical orders, recurring Web3 sales and lower reliance on equity financing.